ArticleMolecular and clinical oncology2025
Neuropilin-1 expression in primary and metastatic prostate cancer: Expression patterns and clinicopathological correlations.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advancements in prostate cancer (PCa) diagnostics, it remains a challenge for accurate diagnosis and effective treatment. The aging global population and the established correlation between PCa incidence and advancing age suggest an anticipated rise in cases. Traditional clinicopathological parameters, such as prostate-specific antigen (PSA) levels, Gleason Grade Group, and pT stage, highlight the need for novel biomarkers to improve prognostic accuracy and risk assessment. The present study investigated the role of neuropilin-1 (NRP-1) in PCa progression, with a focus on lymph node metastases. Findings reveal that higher NRP-1 expression is associated with a lower percentage of metastatic lymph nodes (9.5 vs. 15.0%; P=0.027) and significantly lower postoperative PSA levels (0.02 vs. 0.21 ng/ml, P=0.039), both considered favorable prognostic factors. These observations align with prior hypotheses suggesting that NRP-1's function may depend on its ligand, semaphoring 3A (SEMA3A) or vascular endothelial growth factor (VEGF), with SEMA3A exhibiting anti-tumoral properties in hormone-sensitive PCa. However, NRP-1 expression showed no correlation with key clinicopathological parameters, such as pT stage or Gleason score, nor did it influence 5-year survival rates. These results suggest that while NRP-1 has potential as a biomarker, its prognostic utility as a standalone factor remains limited. Further studies are warranted to validate these findings in larger cohorts and to explore the molecular mechanisms underlying NRP-1's role in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.